{"abstract":"The National Institute of Dental and Craniofacial Research, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patent Applications listed in the Supplementary Information section of this notice to ERYTHRYx Therapeutics, located in Los Angeles, California.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2018/06/22/2018-13443.html","cfr_references":[],"citation":"83 FR 29127","comment_url":null,"comments_close_on":"2018-07-09","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the Office of Technology Transfer and Innovation Access, National Institute of Dental and Craniofacial Research on or before July 9, 2018 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2018-13443","effective_on":null,"end_page":29127,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2018/06/22/2018-13443.xml","html_url":"https://www.federalregister.gov/documents/2018/06/22/2018-13443/prospective-grant-of-an-exclusive-patent-license-methods-of-modulating-erythropoiesis-with-arginine","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2018-13443?publication_date=2018-06-22","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2018-06-22/2018-13443/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":117,"last_updated":"2026-06-25 10:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2018-06-22/pdf/2018-13443.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2018-13443.pdf?1529585132","publication_date":"2018-06-22","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2018/06/22/2018-13443.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T06:37:09Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":29127,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Methods of Modulating Erythropoiesis With Arginine Vasopressin Receptor 1B Molecules","toc_doc":"Methods of Modulating Erythropoiesis with Arginine Vasopressin Receptor 1B Molecules","toc_subject":"Exclusive Patent Licenses; Proposed Approvals:","topics":[],"type":"Notice","volume":83}